Paratek Pharmaceuticals (PRTK) Receives Daily News Impact Score of 0.21
Headlines about Paratek Pharmaceuticals (NASDAQ:PRTK) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.9813939523526 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Major Biotech, Pharma and FDA Catalysts Coming in October (247wallst.com)
- Paratek Pharmaceuticals, Inc. (PRTK) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
- Paratek Pharmaceuticals (PRTK) Presents At Ladenburg Thalmann 2017 Healthcare Conference – Slideshow (seekingalpha.com)
- Paratek Pharmaceuticals, Inc. (PRTK) has a value of $24.70 per share While RXi Pharmaceuticals Corporation (RXII) is … – Stocks Gallery (stocksgallery.com)
- Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017 – GlobeNewswire (press release) (globenewswire.com)
Several equities analysts have recently issued reports on the company. BidaskClub raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 8th. Zacks Investment Research lowered Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. ValuEngine lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Finally, Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and issued a $36.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $37.44.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down 0.40% during trading on Friday, reaching $25.10. The company’s stock had a trading volume of 420,438 shares. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $29.00. The company’s market capitalization is $696.80 million. The firm’s 50-day moving average price is $23.26 and its 200-day moving average price is $21.71.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.25. The firm had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $7.50 million.
In other Paratek Pharmaceuticals news, COO Evan Loh sold 4,351 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $102,596.58. Following the completion of the sale, the chief operating officer now owns 112,783 shares of the company’s stock, valued at approximately $2,659,423.14. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Michael Bigham sold 5,075 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $119,668.50. Following the completion of the sale, the chairman now directly owns 109,500 shares of the company’s stock, valued at approximately $2,582,010. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,365 shares of company stock valued at $409,467. 4.90% of the stock is currently owned by insiders.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.